Momenta To Present At The Canaccord Genuity 32nd Annual Growth Conference

CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Canaccord Genuity 32 nd Annual Growth Conference will be webcast on Wednesday, August 15 at 9:00 a.m. ET.

The audio webcast of the presentation will be available live on the "Investors" section of the company's website located at www.momentapharma.com . A replay of the presentation will be posted on the Momenta website approximately one hour after the event and will be available for two weeks following the presentation.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release.
CONTACT: Lora Pike         Momenta Pharmaceuticals, Inc.         ir@momentapharma.com         617.395.5189

If you liked this article you might like

Teva Must Clear Three Big Hurdles to Reclaim Its Perch

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Sarepta Leads Biotech Movers on Voucher Deal News